Catalyst Biosciences Inc (CBIO) Receives Average Rating of “Strong Buy” from Analysts

Catalyst Biosciences Inc (NASDAQ:CBIO) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.

Analysts have set a 1-year consensus price target of $29.99 for the company and are expecting that the company will post ($7.05) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Catalyst Biosciences an industry rank of 97 out of 265 based on the ratings given to related companies.

Separately, Zacks Investment Research raised shares of Catalyst Biosciences from a “sell” rating to a “hold” rating in a report on Monday, December 26th.

An institutional investor recently raised its position in Catalyst Biosciences stock. Renaissance Technologies LLC raised its position in Catalyst Biosciences Inc (NASDAQ:CBIO) by 105.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 385,450 shares of the biopharmaceutical company’s stock after buying an additional 198,000 shares during the period. Renaissance Technologies LLC owned 3.21% of Catalyst Biosciences worth $251,000 as of its most recent SEC filing. Institutional investors and hedge funds own 33.55% of the company’s stock.

WARNING: “Catalyst Biosciences Inc (CBIO) Receives Average Rating of “Strong Buy” from Analysts” was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at

Catalyst Biosciences (NASDAQ:CBIO) traded down 1.59% on Monday, reaching $4.94. 177,205 shares of the company traded hands. Catalyst Biosciences has a one year low of $4.61 and a one year high of $50.70. The stock’s 50 day moving average price is $6.52 and its 200 day moving average price is $9.56. The company’s market capitalization is $4.94 million.

Catalyst Biosciences (NASDAQ:CBIO) last posted its quarterly earnings data on Wednesday, March 8th. The biopharmaceutical company reported ($4.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($5.63) by $0.95. The company had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.10 million. Catalyst Biosciences had a negative net margin of 4,012.25% and a negative return on equity of 71.57%. On average, equities research analysts predict that Catalyst Biosciences will post ($17.38) EPS for the current fiscal year.

Catalyst Biosciences Company Profile

Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.

5 Day Chart for NASDAQ:CBIO

Get a free copy of the Zacks research report on Catalyst Biosciences (CBIO)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Catalyst Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences Inc and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply